What is the prevalence and clinical characteristics of cutaneous tuberculosis among adult patients with diabetic foot ulcers in a tuberculosis‑endemic region?

Cutaneous Tuberculosis in Diabetic Foot Ulcers: Prevalence and Clinical Characteristics

Cutaneous tuberculosis is a rare but important consideration in diabetic foot ulcers, particularly in TB-endemic regions, though specific prevalence data for this population is not well-established in current literature. Based on available evidence, cutaneous TB should be suspected in any chronic non-healing diabetic foot ulcer that fails to respond to conventional wound care and antibiotics.

Prevalence Context

While the provided guidelines and research do not offer specific prevalence rates of cutaneous TB among diabetic foot ulcer patients, the following epidemiological framework is relevant:

• Cutaneous TB represents only 1-1.5% of all extrapulmonary TB cases 1
• General cutaneous TB prevalence is estimated at 2.1% among all TB manifestations 2
• Diabetes increases TB risk and is associated with altered clinical presentations 3
• The combination of diabetes and chronic wounds creates a unique vulnerability for atypical infections 4

The actual prevalence in diabetic foot ulcer populations remains undefined in current literature, representing a significant knowledge gap, particularly concerning given that diabetic foot infections are the most common diabetes-related complication requiring hospitalization 5.

Clinical Characteristics to Recognize

Presentation Patterns

When cutaneous TB occurs in the context of diabetic foot ulcers, look for these specific features:

Wound Characteristics:

• Chronic non-healing ulcers persisting for months to years despite appropriate conventional therapy 6, 1
• Multiple discharging sinuses with surrounding induration 1
• Undermined wound edges with granulation tissue
• Poor response to standard antibiotics and wound care 1

Clinical Red Flags:

• Ulcer duration >8-12 weeks without improvement despite optimal diabetic foot ulcer management
• Constitutional symptoms may be absent in localized cutaneous disease 6
• Presence of painless ulceration (though neuropathy complicates this assessment)
• Verrucous or papillomatous wound base in some cases

Diagnostic Approach

When cutaneous TB is suspected in a diabetic foot ulcer, pursue tissue-based diagnosis aggressively:

1. Obtain deep tissue biopsy (not superficial swabs) from the ulcer base and edges

2. Send specimens for:

   • Histopathology looking for tuberculoid granulomas with or without caseating necrosis (present in 96% of cases) 2
   • Mycobacterial culture on Löwenstein-Jensen medium 7
   • Molecular testing (CBNAAT/PCR) for rapid diagnosis, especially valuable in paucibacillary disease 4
   • Acid-fast bacilli staining (though sensitivity is limited)

3. Mantoux testing is positive in approximately 83% of cutaneous TB cases 2, but interpret cautiously in diabetic patients with potential immune dysfunction

4. Chest imaging to evaluate for concurrent pulmonary TB 4

Important Clinical Pitfalls

Common diagnostic delays occur because:

• Diabetic foot ulcers are typically polymicrobial, and clinicians focus on common bacterial pathogens 5
• Peripheral neuropathy and vascular disease mask inflammatory signs 5
• Cutaneous TB can mimic many dermatological conditions 1
• Sputum testing may be negative even with concurrent pulmonary involvement 4

The IWGDF/IDSA guidelines emphasize obtaining appropriate specimens for culture in diabetic foot infections 5, but do not specifically address mycobacterial evaluation. In TB-endemic regions or treatment-refractory cases, expand your microbiological workup beyond routine bacterial cultures.

Treatment Considerations

Once diagnosed, cutaneous TB responds excellently to standard anti-tubercular therapy:

• Standard 6-10 month regimen with rifampin, isoniazid, ethambutol, and pyrazinamide 2, 7
• Complete resolution typically achieved by 3 months of treatment 1
• Continue comprehensive diabetic foot ulcer management including offloading, vascular assessment, and glycemic control 5

Critical caveat: The IWGDF/IDSA guidelines note that available data did not allow making recommendations on rifampin use for diabetes-related foot osteomyelitis 5, highlighting the need for infectious disease consultation when TB is confirmed.

Risk Stratification

Maintain higher suspicion in patients with:

• Age ≥60 years (5.7-fold increased TB-diabetes association) 3
• BMI ≥25 kg/m² (5.4-fold increased association) 3
• Family history of diabetes or TB (3.7-fold increased association) 3
• Residence in or travel to TB-endemic regions
• Immunosuppression beyond diabetes alone

In TB-endemic regions, routine screening for diabetes among TB patients shows 22% prevalence 3, suggesting the bidirectional relationship warrants attention in both directions.